Table 1 Patient characteristics at diagnosis and treatments before high-dose chemotherapy

No.	Age	Sex	Primary location	Histology	Increased markers	Metastatic sites	Primary treatment	Response
1	1	M	Sacr	EC, IT	AFP=794	Lung	RPTR; Cis, Vbl, Bl, VP16, Ifo (Adj)	CR
2	1	F	Sacr	NSGCT	AFP=22 250	Liver, B	RPTR; Cis, Vbl, Bl, VP16, Ifo, AcD, Cy; PRLM	PR+
3	13	M	CNS	Unknown	AFP=3710	None	Carbop, VP16, Ifo	PD
4	15	F	CNS	Germin	None	None	RT-CNS; Cis, Vbl, Bl, VP16, Ifo	CR
5	1	F	Sacr	NSGCT	AFP=54 290, LDH=931	None	PPTR; CT	PR+
6	1	F	Sacr	NSGCT	AFP=13 750	Bone	Cis, Vbl, Bl	CR
7	13	M	CNS	MT, YST	AFP=305	None	Carbop, VP16, Bl	PR+
8	14	M	CNS	Unknown	AFP/HCG exact values unknown	None	Cis, VP16, Bl; RT-CNS	CR
9	1	M	Sacr	YST	AFP=10 4000	Retr, Liver	Cis, Vcr, Ifo, Carbop, Vbl, Bl,	PR−
10	11	M	CNS	EC	AFP=43; HCG=142	None	RT-CNS; Cis, Vcr, VP16, Cy	PR−
11	13	M	Med	NSGCT	AFP=6100; HCG=920	None	Carbop, Vbl, Bl, AcD	PR+
12	6	F	Sacr	EC, YST	HCG=18 042; LDH=999	Med, CNS, Lung, B	Cis, Vcr, Mtx, Bl, AcD, Cy, VP16	PD
13	18	M	CNS	EC, MT	AFP=416; HCG=30; LDH=1149	None	RT-CNS	PR−
14	7	M	CNS	Unknown	AFP=145, HCG=53	None	RT-CNS	CR
15	1	F	Sacr	EC	AFP=46 100	None	PPTR; Carbop, Cy, AcD, Vbl, Bl	CR
16	9	M	Retr	NSGCT	Unknown	None	RPTR; Vcr, AcD (Adj)	CR
17	12	M	CNS	Unknown	AFP=339	None	CT; RT-CNS	PR+
18	1	F	Sacr	YST	AFP=30 947, LDH=828	Retr, Liver	Cis, Vbl, Bl, VP16, Ifo, AcD	CR
19	19	M	CNS	CC	HCG=40 400	Lung	CT; RT-CNS	PD
20	11	M	Med	EC, YST	None	None	RPTR; Cis, VP16, Bl (Adj)	CR
21	7	M	Retr	NSGCT	Unknown	None	PPTR; Cis, VP16, Bl	PR+
22	4	F	Retr	YST	AFP=27 8000, LDH=1786	Liver	Cis, Vbl, Bl, VP16, Ifo	CR
23	1	F	Retr	EC	AFP=14 8600	None	PPTR; Cis, VP16, Bl	PR+

M, male; F, female; Sacr, sacrococcix; CNS, central nervous system; Med, mediastinum; Retr, retroperitoneum; B, bone; IT, immature teratoma; MT, mature teratoma; YST, yolk sac tumour; EC, embryonal carcinoma; CC, choriocarcinoma; Germin, germinoma; NSGCT, nonseminomatous germ-cell tumour (not furthermore specified); AFP, alpha-fetoprotein (ng ml⁻¹); HCG, human choriogonadotropin (IU l⁻¹); RPTR, radical primary tumour resection; PPTR, partial primary tumour resection; PRLM, partial resection liver metastases; Cis, cisplatin; Vbl, vinblastin; Bl, bleomycin; VP16, etoposide; Ifo, ifosfamide; AcD, actinomycin D; Cy, cyclophosphamide; Carbop, carboplatin; Vcr, vincristine; Mtx, methotrexate; CT, chemotherapy (schedule/drugs not available); RT, radiotherapy; Adj, adjuvant; CR, complete remission; PR−, marker-negative partial remission; PR+, marker-positive partial remission; SD, stable disease; PD, progressive disease.

Search